Huntington’s disease is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene, which produces a toxic mutant protein that progressively destroys neurons, particularly in the striatum and cortex. Symptoms typically emerge in midlife and include involuntary choreiform movements, cognitive decline, psychiatric disturbance, and profound metabolic abnormalities. Patients commonly experience unintended weight loss, altered glucose metabolism, mitochondrial dysfunction, and disrupted circadian rhythms—features that worsen as the disease advances and that strongly predict clinical progression. Body weight, in fact, is a robust predictor of how quickly the disease moves, and metabolic disturbances have been documented in the muscle, fibroblasts, and brains of affected individuals for decades. Despite an intense global research effort, including recent phase 3 trials of pridopidine and the antisense oligonucleotide tominersen, no therapy has yet been shown to decisively alter the disease course.

It is precisely this metabolic signature that made time-restricted eating an attractive candidate. In preclinical work, dietary restriction and intermittent fasting normalized glucose metabolism, elevated brain-derived neurotrophic factor, slowed disease progression, and extended survival in mutant huntingtin mice. Time-restricted feeding improved circadian dysfunction and motor symptoms in the Q175 mouse model, and circadian-based treatment strategies proved effective in the BACHD mouse model. Mechanistically, researchers believe the benefits stem from intermittent metabolic switching: the periodic transition from glucose-based fuel to ketone bodies and fatty acid oxidation that occurs during fasting windows. This metabolic switch triggers a cascade of adaptive responses, including enhanced autophagy—the cellular housekeeping process that clears damaged proteins, including mutant huntingtin aggregates—alongside improved mitochondrial function, reduced inflammation, and changes in circulating factors such as growth hormone, ghrelin signaling modulators like LEAP2, FGF21, and bile acids. The gut microbiota may also mediate some of the cognitive benefits observed with intermittent fasting in animal studies.

The new trial, registered as NCT06490367, enrolled 20 individuals with early-stage manifest Huntington’s disease in a 12-week open-label pilot study. Participants were asked to consume all of their daily calories within an eight-hour window, alongside standard-of-care diet and activity recommendations. The design deliberately avoided calorie counting or prescribed diets, isolating the timing of eating as the sole variable. Adherence was tracked through self-reported daily eating intervals and corroborated with time-stamped smartphone application data, which showed strong agreement between the two measures. Participants successfully compressed their eating windows from baseline habits, shifting the timing of both first and last caloric intake without substantially altering sleep onset or wake times—a critical point, since the intervention appeared to act on meal timing rather than simply disrupting sleep patterns.

The results were encouraging on multiple fronts. First, the intervention proved feasible: participants sustained the eight-hour eating window across the trial period with adherence rates indicating that most days met the protocol definition. Second, the regimen was well tolerated, an important consideration in a population at risk of weight loss, where aggressive caloric restriction could be harmful. Notably, the trial paired time-restricted eating with standard nutritional guidance precisely to guard against unintended weight decline. Third, and most strikingly, the researchers observed favorable changes in clinical measures of Huntington’s disease, including components of the composite Unified Huntington’s Disease Rating Scale, a validated outcome measure designed to capture clinically meaningful change in early-stage patients. In a disease defined by steady deterioration, even short-term stability or improvement on such measures in a small uncontrolled trial is noteworthy, though the authors and outside experts alike caution that practice effects and the absence of a control group make it impossible to attribute the changes confidently to the intervention.

Perhaps the most provocative finding concerned plasma neurofilament light chain, a protein released when neurons are injured that has emerged as one of the most reliable fluid biomarkers of neurodegeneration. Five-year longitudinal analyses have shown that plasma neurofilament light tracks neurodegeneration across the Huntington’s disease spectrum, and it is increasingly used as a secondary endpoint in therapeutic trials. In this pilot, levels of the biomarker moved in a favorable direction over the 12-week intervention, hinting—tentatively—that time-restricted eating might influence the very process of neuronal injury. The researchers also examined peripheral mitochondrial bioenergetics by measuring oxygen consumption rates in peripheral blood mononuclear cells using a mitochondrial stress test protocol, assessing basal respiration, ATP-linked respiration, maximal respiration, and spare respiratory capacity before and after the intervention. Given the well-documented mitochondrial dysfunction in Huntington’s disease, including transcriptional repression of PGC-1α by mutant huntingtin, these cellular energy measurements provide a mechanistic window into how a dietary intervention might interact with the disease’s underlying bioenergetic deficits.

The trial also monitored a broad panel of secondary outcomes reflecting the metabolic and inflammatory dimensions of the disease. Researchers assessed body composition, sleep quality using the Pittsburgh Sleep Quality Index, cognition with the Montreal Cognitive Assessment, and dietary quality using tools including the dietary inflammatory index and a Mediterranean diet score—an important control, since pro-inflammatory dietary patterns have been linked to dementia incidence in population studies. This comprehensive phenotyping reflects a deliberate strategy: rather than betting on a single endpoint, the pilot was designed to map the full physiological footprint of time-restricted eating in this population, generating hypotheses and effect-size estimates to power larger controlled trials. All source data from the study have been made publicly available through a Mendeley Data repository, and the trial protocol itself was published in advance in PLoS ONE, exemplifying the transparent, staged approach increasingly favored for lifestyle intervention research.

Experts in the field emphasize both the promise and the limitations of the work. As an open-label study without a placebo group, the trial cannot exclude expectation effects, regression to the mean, or practice effects on repeated neuropsychological testing, phenomena that are well documented in Huntington’s disease cohorts and even proposed as dynamic biomarkers of early cognitive change. The sample of 20 participants, while adequate for establishing feasibility, is far too small to detect the modest treatment effects that have frustrated large pharmaceutical trials. The history of Huntington’s disease research is littered with interventions that looked promising in early-phase studies—often with biomarker signals similar to those reported here—only to fail in definitive testing. Modeling work drawing on the Enroll-HD and GENERATION HD1 cohorts has highlighted how difficult it is to distinguish true disease modification from placebo response and natural variability in progression rates.

Nevertheless, the study represents a genuine milestone: the first time a fasting-based intervention has been formally tested in people with Huntington’s disease, translating nearly two decades of preclinical evidence into the clinic. If larger randomized controlled trials confirm that simply restricting the daily eating window can stabilize clinical measures and favorably shift neurodegeneration biomarkers, the implications would extend far beyond this single rare disease. Time-restricted eating is inexpensive, scalable, and already practiced by millions worldwide for weight management and metabolic health. A rigorous demonstration of neuroprotective effects would position meal timing as a genuine therapeutic modality for the brain. For now, the researchers urge restraint: the findings support the need for further investigation, not immediate clinical recommendations. But for a community that has endured decades of therapeutic disappointment, the idea that the clock, as much as the kitchen, might shape the course of Huntington’s disease is a source of hard-won and carefully qualified hope.

Subject of Research: Time-restricted eating as a lifestyle intervention in early-stage Huntington's disease

Article Title: Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study

Article References: Wells, R. G., Neilson, L. E., McHill, A. W., Gray, N. E., Quinn, J. F., & Hiller, A. L. (2026). Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study. Nature Metabolism. https://doi.org/10.1038/s42255-026-01612-x

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01612-x

Keywords: Huntington's disease, time-restricted eating, intermittent fasting, neurodegeneration, neurofilament light, mitochondrial dysfunction, circadian rhythms, autophagy, pilot trial, metabolism, biomarkers, lifestyle intervention

Huntington’s disease is an inherited, progressive brain disorder caused by an expanded CAG repeat in the huntingtin gene. The mutation produces a toxic protein that gradually damages striatal and cortical neurons, giving rise to a characteristic combination of involuntary movements, cognitive decline and psychiatric disturbance. There is currently no therapy that slows the underlying neurodegenerative process; available drugs manage symptoms, chiefly the movement disorder, while the disease continues its course over one to two decades. Against that backdrop, interventions that target the metabolic environment of vulnerable neurons have attracted growing interest, because mounting evidence suggests that mitochondrial dysfunction and altered energy metabolism are central players in the disease process rather than incidental byproducts of it.

The scientific rationale for testing fasting in Huntington’s disease stretches back more than two decades. In 2003, a team led by Wenzhen Duan reported in the Proceedings of the National Academy of Sciences that dietary restriction normalized glucose metabolism and slowed disease progression in a mouse model of the disorder — the first preclinical demonstration that manipulating meal timing could influence the course of Huntington-like pathology. That observation languished in relative obscurity for years, but it seeded a line of research that matured into a comprehensive review published in Translational Neurodegeneration in 2024, in which R. G. Wells, L. E. Neilson, A. W. McHill and A. L. Hiller synthesized the animal evidence on dietary fasting and time-restricted eating in Huntington’s disease and proposed mechanisms through which periodic metabolic stress might protect the fragile neurons that die first in patients.

Those proposed mechanisms converge on a handful of interconnected pathways. Fasting periods activate cellular stress-response programs, including autophagy, the cellular housekeeping system that clears damaged proteins and organelles — a process of particular relevance in Huntington’s disease, where misfolded mutant huntingtin protein accumulates inside neurons. Fasting also promotes mitochondrial biogenesis and improves metabolic flexibility, the capacity of cells to switch between glucose and fatty-acid fuel sources. Impaired glucose metabolism and mitochondrial dysfunction are well documented in the disease, and studies of patient-derived fibroblasts have shown that lower mitochondrial oxygen consumption is associated with an earlier age of motor onset, independent of CAG repeat size. In other words, the bioenergetic state of a patient’s cells appears to help determine how quickly the disease unfolds, raising the possibility that interventions which improve cellular energy handling could shift that trajectory.

Translating that biology into a human trial required answering a practical question first: can people with early-stage Huntington’s disease actually adhere to a compressed eating window, and is the regimen safe for a patient population that often struggles with weight loss, swallowing difficulties and heightened metabolic demand? Patients with Huntington’s disease frequently become cachectic as the disease advances, so any dietary intervention that risks accelerating weight or muscle loss would be a non-starter. The trial protocol, published in PLoS ONE in 2025 by the same group, was designed explicitly to test feasibility and tolerability alongside exploratory signals of efficacy, using a twelve-week interventional design in twenty participants with early-stage disease.

The results, now summarized in Nature Metabolism as a Research Briefing accompanying the full pilot study by Wells and colleagues, indicate that the intervention was feasible and well tolerated across the study period. Participants restricted their eating to a daily window of six to eight hours — a form of intermittent fasting that does not require caloric counting or outright fasting days, only a consistent daily schedule. That operational simplicity matters for clinical translation, because adherence is the perennial Achilles heel of dietary interventions, and regimens that demand extreme restriction rarely survive contact with real-world patient life. The pilot’s central achievement is demonstrating that a meaningful fasting window can be implemented in this population without evident harm.

Beyond tolerability, the exploratory analyses generated signals that will shape the design of larger trials. The researchers observed improvements in clinical measures, in plasma neurofilament light and in cellular bioenergetics. Neurofilament light is a structural protein released into the cerebrospinal fluid and blood when axons are injured, and it has emerged as one of the most informative fluid biomarkers of neurodegeneration across a range of disorders. A five-year longitudinal study published in eBioMedicine in 2024 by G. M. Parkin, E. A. Thomas and J. Corey-Bloom mapped the expected annual rise in plasma neurofilament light across the Huntington’s disease spectrum, providing the reference framework against which the changes observed in the fasting pilot can be interpreted. A biomarker trajectory that bends away from the expected rise over twelve weeks is not proof of neuroprotection, but it is exactly the kind of signal that justifies investing in a definitive trial.

The bioenergetics findings connect the human results back to the mechanistic work in cells and animals. Because mitochondrial respiratory capacity in patient cells has been linked to disease onset and progression, measuring cellular energy metabolism before and after the intervention offers a way to ask whether time-restricted eating changes the fundamental metabolic physiology that theory says it should. The pilot’s exploratory improvements in this domain suggest that the intervention engaged the biology it was designed to target, rather than merely changing eating schedules. Body composition and clinical measures were also tracked, addressing the critical safety question of whether compressed eating windows exacerbate the weight loss that plagues many patients — and the reported tolerability indicates the regimen did not produce overt deterioration over the study period.

Caution remains essential at this stage. A pilot study with twenty participants, no control group described in the available summary and exploratory rather than pre-specified confirmatory analyses cannot establish efficacy, and biomarker fluctuations over twelve weeks can reflect measurement variability, seasonal effects or regression to the mean as easily as biological change. The appropriate reading of the work is as a proof of feasibility and signal generation: the study establishes that the intervention can be delivered, that it appears safe in the short term and that its hypothesized targets — neurodegeneration biomarkers and cellular energy metabolism — move in a direction consistent with benefit. Definitive claims will require randomized, controlled trials with larger cohorts, longer follow-up and adequate statistical power, ideally stratified by disease stage and CAG repeat length.

Even so, the significance of the work extends beyond Huntington’s disease. It represents a template for how metabolic interventions long confined to animal models and healthy-volunteer studies can be brought to neurodegenerative populations with careful attention to their specific vulnerabilities. Fasting-based approaches are being explored in Parkinson’s disease, multiple sclerosis and other neurological conditions, and the Huntington’s pilot provides one of the first direct human data points in a monogenic neurodegenerative disorder, where biomarkers are unusually well characterized and disease progression can be tracked with precision. If larger trials confirm that something as simple as when patients eat — independent of what or how much — can alter the trajectory of a fatal genetic brain disease, the implications for how medicine thinks about meal timing would be profound. For now, the message to patients is one of tempered optimism: the evidence is early, the trials are small, and no one should undertake extended fasting without medical supervision. But the door that Duan’s mice opened in 2003 has now been walked through by human patients, and the field will be watching closely to see what lies on the other side.

Subject of Research: Clinical testing of time-restricted eating as an intermittent fasting intervention in early-stage Huntington's disease

Article Title: Meal timing as medicine: clinical evidence for intermittent fasting in Huntington’s disease

Article References: Meal timing as medicine: clinical evidence for intermittent fasting in Huntington’s disease. (2026). Nature Metabolism. https://doi.org/10.1038/s42255-026-01613-w

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01613-w

Keywords: Huntington's disease, time-restricted eating, intermittent fasting, neurofilament light, mitochondrial bioenergetics, neurodegeneration, pilot study, metabolism, clinical trial, dietary restriction, Nature Metabolism, biomarkers

The study was led by Sue Shapses, PhD, RD, DFASN, of Rutgers University and Rutgers–RWJ Medical Center. The trial is designed around a calorie reduction strategy paired with either a narrower or typical daily eating schedule. Participants were counseled to cut 500 calories per day to standardize energy intake across groups.

Forty-seven women aged 50–79 were enrolled. All reduced calories, but 26 participants were assigned to restrict eating to a window of fewer than 9 hours per day, while the remaining group maintained an approximately 12-hour window. In practice, the time-restricted group typically ate from about 10 a.m. to 6 p.m., yielding an average eating window of 8.2 hours, compared with 12.3 hours for the control window.

After six months, both groups lost weight—about 15 pounds on average—with no meaningful difference between groups. This allowed the researchers to examine whether cognitive changes track with eating-window compression rather than weight loss per se.

Cognitive testing showed that the shorter-window group improved performance on spatial planning and problem-solving tasks at the end of the weight-loss program. A trend toward fewer errors on memory and learning measures was also observed, although multitasking and reaction-time outcomes did not differ significantly.

Shapses said the effects were modest but meaningful, linking reduced eating windows to improved ability to remember information in everyday contexts and to make fewer errors associated with memory, attention, and problem-solving. Notably, the size of the cognitive improvements increased as the eating window shortened.

Because the trial was small, the authors emphasize the need for larger, more definitive studies. They also plan mechanistic work to explain how early stopping and circadian alignment might influence nutrient-sensing pathways, inflammation, and metabolic health—processes implicated in cognitive aging.

The findings will be presented at NUTRITION 2026, the American Society for Nutrition’s flagship meeting, during the Aging and Chronic Disease (II) Poster Session on Sunday, July 26, from 9:30–10:30 a.m. EDT. The organizers note that abstracts selected for the meeting are not routinely peer-reviewed in the same way as journal articles, so the results should be considered preliminary until published in a peer-reviewed format.

Subject of Research: Time-restricted eating and cognitive outcomes in older women
Article Title: Not provided
News Publication Date: July 26, 2026
Web References: Provided in the original content (abstract PDF and presentation details link)
References: Not provided
Image Credits: Not provided

Keywords: time-restricted eating, dementia risk, cognitive decline, circadian rhythm, older adults, clinical trial, Alzheimer disease, metabolic health, nutrient sensing